Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer IndexSM (BCI).
Weighing the value that emerging therapies have for improving outcomes and significantly impacting quality of life against the cost of care is a challenge for all stakeholders involved in managing patients with PV.
Listen as some of the top academic and community thought leaders in multiple myeloma define what precision medicine means to them.
Highlights from the Third Annual World Cutaneous Malignancies Congress Conference in San Francisco, California
Highlights from the Third Annual PMO Live Conference, a Global Biomarkers Consortium Initiative, in San Francisco, California